Overview

Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Status:
Recruiting

Trial end date:
2022-10-30

Target enrollment:
0

Participant gender:
All

Summary

The aim of this single-center prospective study is to evaluate the efficacy and feasibility of Metoprolol, a beta-blocker, in the treatment of cytokine release syndrome (CRS) caused by Chimeric antigen receptor T (CART) cells, to verify its effects on decreasing the level of Interleukin-6 (IL-6), and to determine whether it can replace the intervention of other antibodies, such as tocilizumab.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chinese PLA General Hospital

Treatments:

Antibodies
Metoprolol

Criteria

Inclusion Criteria:

- Male or female participant 18 Years to 70 Years Patients with malignant tumors who
received the treatment of CART cells. Estimated life expectancy ≥ 12 weeks (according
to investigator's judgement) Eastern Cooperative Oncology Group (ECOG) performance
status ≤ 2 Adequate organ function

Exclusion Criteria:

- Significant bradycardia (heart rate < 45/min) cardiogenic shock severe or acute heart
failure poor peripheral circulation perfusion degree II or III atrioventricular block
sick sinus syndrome severe peripheral vascular disease